Literature DB >> 1419641

The selection of cases for randomised trials: a registry survey of concurrent trial and non-trial patients. The British Stomach Cancer Group.

L C Ward1, J W Fielding, J A Dunn, K A Kelly.   

Abstract

A randomised trial of adjuvant chemotherapy vs placebo in operable stomach cancer recruited 249 patients from the West Midlands Region between 1976-1980. A Cancer Registry survey identified a further 1261 suitable concurrent cases. Trial patients were compared with the 960 non-trial cases from participating Districts. Only 493 (51%) non-trial cases passed all of the prospective trial selection criteria for entry. Stage and fitness caused the majority of exclusions and were also highly prognostic. A univariate analysis comparing eligible patients with the trial showed the two groups to be balanced for the significant independent prognostic factors of the trial. However, differences in patient age and the surgery performed indicate that recruitment may have been influenced by unknown selection factors. This survey highlights the difficulty of retrospective selection and confirms the need for randomised controls. Data available from specialist Registries may be used to help develop new protocols and to verify and extend trial results.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1419641      PMCID: PMC1977993          DOI: 10.1038/bjc.1992.390

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  CARCINOMA OF THE STOMACH: A 10-YEAR SURVEY OF RESULTS AND OF FACTORS AFFECTING PROGNOSIS.

Authors:  V S BROOKES; J A WATERHOUSE; D J POWELL
Journal:  Br Med J       Date:  1965-06-19

2.  Ethical implications of rejecting patients for clinical trials.

Authors:  T C Chalmers
Journal:  JAMA       Date:  1990-02-09       Impact factor: 56.272

3.  Survival of patients with cancer.

Authors:  C A Stiller
Journal:  BMJ       Date:  1989-10-28

4.  Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party.

Authors:  T Bates; D L Riley; J Houghton; L Fallowfield; M Baum
Journal:  Br J Surg       Date:  1991-05       Impact factor: 6.939

5.  Eligibility and extrapolation in cancer clinical trials.

Authors:  C B Begg; P F Engstrom
Journal:  J Clin Oncol       Date:  1987-06       Impact factor: 44.544

6.  Non-randomized controls in cancer clinical trials.

Authors:  E A Gehan; E J Freireich
Journal:  N Engl J Med       Date:  1974-01-24       Impact factor: 91.245

Review 7.  Beyond randomized clinical trials: applying clinical experience in the treatment of patients with coronary artery disease.

Authors:  R M Califf; D B Pryor; J C Greenfield
Journal:  Circulation       Date:  1986-12       Impact factor: 29.690

8.  What sort of oncology team should treat testicular teratoma?

Authors:  K D Bagshawe; R H Begent; E S Newlands; G J Rustin
Journal:  Lancet       Date:  1985-04-20       Impact factor: 79.321

9.  Randomised comparative studies in the treatment of cancer in the United Kingdom: room for improvement?

Authors:  H C Tate; J B Rawlinson; L S Freedman
Journal:  Lancet       Date:  1979-09-22       Impact factor: 79.321

10.  Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial.

Authors:  W H Allum; M T Hallissey; K A Kelly
Journal:  Lancet       Date:  1989-03-18       Impact factor: 79.321

View more
  11 in total

Review 1.  The rationale for a spine registry.

Authors:  C Röder; U Müller; M Aebi
Journal:  Eur Spine J       Date:  2005-11-16       Impact factor: 3.134

2.  Why we need observational studies to evaluate the effectiveness of health care.

Authors:  N Black
Journal:  BMJ       Date:  1996-05-11

3.  Does enrollment in cancer trials improve survival?

Authors:  Christopher J Chow; Elizabeth B Habermann; Anasooya Abraham; Yanrong Zhu; Selwyn M Vickers; David A Rothenberger; Waddah B Al-Refaie
Journal:  J Am Coll Surg       Date:  2013-02-13       Impact factor: 6.113

Review 4.  Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials.

Authors:  Andrew Anglemyer; Hacsi T Horvath; Lisa Bero
Journal:  Cochrane Database Syst Rev       Date:  2014-04-29

5.  Recruitment of patients with lung cancer into a randomised clinical trial: experience at two centres. On behalf of the Big Lung Trial Steering Committee.

Authors:  S G Spiro; N H Gower; M T Evans; F M Facchini; R M Rudd
Journal:  Thorax       Date:  2000-06       Impact factor: 9.139

6.  Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010.

Authors:  Francesca Nava; Irene Tramacere; Andrea Fittipaldo; Maria Grazia Bruzzone; Francesco Dimeco; Laura Fariselli; Gaetano Finocchiaro; Bianca Pollo; Andrea Salmaggi; Antonio Silvani; Mariangela Farinotti; Graziella Filippini
Journal:  Neuro Oncol       Date:  2014-01-23       Impact factor: 12.300

Review 7.  Osteoporosis therapies: evidence from health-care databases and observational population studies.

Authors:  Stuart L Silverman
Journal:  Calcif Tissue Int       Date:  2010-08-20       Impact factor: 4.333

8.  Comparison of survival outcomes among cancer patients treated in and out of clinical trials.

Authors:  Joseph M Unger; William E Barlow; Diane P Martin; Scott D Ramsey; Michael Leblanc; Ruth Etzioni; Dawn L Hershman
Journal:  J Natl Cancer Inst       Date:  2014-03-13       Impact factor: 13.506

Review 9.  Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate.

Authors:  Gunn Elisabeth Vist; Dianne Bryant; Lyndsay Somerville; Trevor Birminghem; Andrew D Oxman
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

10.  Centralised treatment, entry to trials and survival.

Authors:  C A Stiller
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.